top of page
Search

Know Labs Furthers External Validation of Bio-RFID™ with Study Published in Sensors Journal

Study conducted in collaboration with Mayo Clinic demonstrates accuracy of Bio-RFID and supports the technology’s application in non-invasive bio-monitoring.


SEATTLE May 18, 2023 Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the publication of its first peer-reviewed study in Sensors Journal. The manuscript titled, Detecting Unique Analyte-Specific Radio Frequency Spectral Responses in Liquid Solutions—Implications for Non-Invasive Physiologic Monitoring, describes the proof-of-principle study of Know Labs’ Bio-RFID technology that quantified different analytes in vitro, proving a 100% accuracy rate. Sensors is the leading international, peer-reviewed, open access journal on the science and technology of sensors.


The publication of the full manuscript comes just one month after Know Labs announced the study abstract and results via a press release, which underwent review by the American Physiological Society (APS) Program Committee before presentation at the 2023 APS Summit.


“This is a big milestone for us,” said Ron Erickson, CEO and Chairman at Know Labs. “The first of many peer-reviewed publications of Know Labs’ research is significant in validating our Bio-RFID technology on the road towards delivering the first FDA-cleared, truly non-invasive glucose monitoring device to the market. We have a lot more firsts on the horizon, and we’re eager to share what’s next.”


This journal publication contributes to the growing body of peer-reviewed research that Know Labs is conducting as the company prioritizes external validation of its Bio-RFID technology in detecting and measuring glucose and other analytes in the body non-invasively at high levels of accuracy.


“We’re excited to publish this research in a scientific journal like Sensors to validate the work being done at Know Labs that is truly revolutionary,” said James “Andy” Anderson, M.D., Chief Medical Officer at Know Labs. “Know Labs is one step closer to bringing its non-invasive glucose monitoring technology to the masses, and that is something that will change modern medicine as we know it.”


To learn more about Know Labs and the ongoing series of research studies being conducted by the company, visit www.knowlabs.co/research-and-validation.


Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.


About Know Labs, Inc.

Know Labs, Inc. is a public company whose shares trade on the NYSE American Exchange under the stock symbol “KNW.” The Company’s technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The Company refers to its technology as Bio-RFID™. The Bio-RFID technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of our Bio-RFID technology will be in a product marketed as a non-invasive glucose monitor. It will provide the user with real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration clearance prior to its introduction to the market.


Safe Harbor Statement

This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2022, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.


For Know Labs Media Inquiries Contact: Matter Health Laura Bastardi Knowlabs@matternow.com Ph. (603) 494-6667


Know Labs, Inc. Contact: Jordyn Hujar jordyn@knowlabs.co Ph. (206) 629-6414

230 views

Recent Posts

See All

Know Labs, Inc. Reports First Quarter FY2024 Results

SEATTLE – February 14, 2024 – Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the first quarter ended De

bottom of page